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SUMMARY
The eﬀectiveness of inﬂuenza vaccination programmes is seldom known during an epidemic.
We developed an internet-based system to record inﬂuenza-like symptoms and response to
infection in a participating cohort. Using self-reports of inﬂuenza-like symptoms and of
inﬂuenza vaccine history and uptake, we estimated vaccine eﬀectiveness (VE) without the need
for individuals to seek healthcare. We found that vaccination with the 2010 seasonal inﬂuenza
vaccine was signiﬁcantly protective against inﬂuenza-like illness (ILI) during the 2010–2011
inﬂuenza season (VE 52%, 95% CI 27–68). VE for individuals who received both the 2010
seasonal and 2009 pandemic inﬂuenza vaccines was 59% (95% CI 27–77), slightly higher than
VE for those vaccinated in 2010 alone (VE 46%, 95% CI 9–68). Vaccinated individuals with ILI
reported taking less time oﬀ work than unvaccinated individuals with ILI (3.4 days vs. 5.3 days,
P<0.001).
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INTRODUCTION
Many countries routinely vaccinate against inﬂuenza.
However, as vaccines must be developed before the
inﬂuenza season, mismatches between the circulating
and vaccine strains can occur. It is therefore seldom
clear during the season how eﬀective the vaccine is
at reducing the risk of death, serious illness, inﬂuenza-
like illness (ILI), laboratory-conﬁrmed disease,
absenteeism, or other adverse events.
Measuring vaccine eﬀectiveness (VE) can be chal-
lenging because of the many potential confounders
and biases. The ‘gold-standard’ approach involves
following large matched cohorts of vaccinated and
unvaccinated individuals over the course of a season
and directly measuring the protective eﬀect of the
vaccine. In practice, such cohort studies are rarely
used as they are both time-consuming and expensive.
Instead, a range of alternative techniques has been
developed to estimate VE more rapidly and with
fewer resources [1–4].
Commonly reported techniques include the screen-
ing method and the case-control method [1, 2]. The
screening method compares vaccination levels in
inﬂuenza cases that are seen by the health services
with estimated vaccination levels in the population as
a whole, whereas the case-control method compares
vaccination levels in ILI cases that are laboratory
conﬁrmed as inﬂuenza with ILI cases that test
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negative for inﬂuenza. These methods were used to
estimate the eﬃcacy of the H1N1v (2009) vaccine
during the 2009–2010 season to be 70% in England
and Scotland [5], and around 90% in Germany [6]
and Canada [7], and have been applied elsewhere in
previous inﬂuenza seasons [3, 4, 8]. The ﬁrst estimates
of the eﬃcacy of the 2010 seasonal inﬂuenza vaccine,
obtained using the case-control method, were recently
published [9], suggesting an eﬃcacy of around 63%
in people vaccinated in both the 2009–2010 and
2010–2011 seasons.
Although widely used, these methods suﬀer from
the fact that they require cases to present themselves
for detection, generally to general practitioners (GPs),
and to be identiﬁed as ILI cases and tested for inﬂu-
enza. It is highly unlikely that individuals with ILI
who are tested for inﬂuenza by their GP are a random
sample of individuals with ILI [10]. In particular, such
eﬃcacy estimates depend on assumptions about the
relative rates of treatment-seeking and case-detection
in vaccinated and unvaccinated individuals. There are
a number of possible ways in which these assumptions
may not be met: incidence of inﬂuenza-negative ILI
may diﬀer between vaccinated and unvaccinated
groups; there may be diﬀerences in the presentation
of symptoms between vaccinated and unvaccinated
individuals, leading to diﬀerences in the probability of
cases being identiﬁed for testing by GPs; there may
be diﬀerences in viral shedding levels or duration of
infectiousness leading to diﬀerences in test sensitivity.
These reasons provide motivation for seeking ad-
ditional methods of estimating VE that do not rely on
individuals presenting themselves for treatment.
Here, we present a novel method for monitoring
VE in real-time using an internet-based cohort [11, 12].
In contrast to other methods, internet-based sur-
veillance does not rely on individuals seeking medical
attention [10]. During a normal inﬂuenza season,
internet surveillance can complement traditional
methods by providing rapid preliminary estimates of
VE and may prove vital during a pandemic when
traditional surveillance methods are not practical
[11, 12].
METHODS
The internet-based UK ﬂusurvey (www.ﬂusurvey.
org.uk) [11] was launched for the 2010–2011 season
on 1 December 2010. Participation was voluntary,
and members of the public were encouraged to par-
ticipate through outreach activities and the media.
Participants completed an intake questionnaire on
registration, recording their age, gender, risk group
status (taking regularmedication for diabetes, asthma,
other lung, heart or kidney disorders, being immuno-
compromised or pregnant), whether and when they
were vaccinated, public transport use, and contact
with groups of patients, the elderly, and children.
Each week, participants were prompted by email
to complete a survey documenting any symptoms
experienced, onset date, use of health services, and
whether the episode resulted in absenteeism. Further
details can be found in Tilston et al. [11]. Participants
were able to update their reported vaccination
status throughout the season, and were periodically
reminded of this in the weekly email.
We analysed all reports collected up to 31 January
2011 from all participants who had completed the
symptom questionnaire at least once. The study
period, 1 December 2010 to 31 January 2011, includes
the time during which GP-reported levels of ILI
peaked and were above baseline levels (Fig. 1).
Episodes of illness reported through ﬂusurvey were
classiﬁed as ILI if the recorded symptoms matched
the Health Protection Agency (HPA) ILI case deﬁ-
nition of a fever plus two or more of: cough, sore
throat, runny nose, joint pain, headache, vomiting or
diarrhoea. Episodes of acute respiratory illness that
did not match the ILI case deﬁnition but included
symptoms of sneezing, cough, runny/blocked nose
or sore throat were diagnosed as milder respiratory
illness (MRI).
An unadjusted estimate of VE was estimated from
the ratio of attack rates in vaccinated and un-
vaccinated participants as 1 – RR, where RR is the
relative risk of reporting illness in the vaccinated and
unvaccinated groups. As this crude estimate of VE
is not adjusted for any covariates, such as age or
belonging to a risk group, multivariate regression
models were used to model the probability of ever
reporting ILI and, for those individuals who did not
report ILI, ever reporting MRI during the study per-
iod. Age group, membership of a risk group, contact
patterns and vaccine status were used as predictor
variables. For the purposes of this study, participants
were considered as vaccinated during the 2010–2011
season if they reported having received a vaccine at
any stage during the season. Because of the timing
of the study, the majority of those vaccinated had
received their vaccine before the study began (Fig. 1).
VE is deﬁned as the relative reduction in risk
between the vaccinated and unvaccinated groups.
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Because ILI is relatively common, Poisson regression
with robust standard errors was used to estimate
directly the RR of reporting ILI given each of the
predictor variables [13] (the common approach of
using the odds ratio (OR) to approximate RR is
only appropriate when measuring rare events [13]).
Estimates generated using log-binomial regression
[13, 14] and adjusting ORs using the method of Zhang
& Yu [15] gave very similar results (not shown).
Analyses were conducted using R version 2.10 [16]
and Stata v. 11 [17].
RESULTS
In all, 653 individuals registered for the ﬂusurvey, of
whom six were excluded from the analysis because of
unknown vaccine status. The symptom questionnaire
was completed a total of 3102 times, with a median of
ﬁve reports per participant.
Table 1 shows the characteristics of the 647 in-
dividuals included in the analysis. Sixty-two percent
of participants were female and, as might be expected
from an internet-based survey, children and people
agedo65 years were underrepresented, with 78% of
participants aged between 25 and 64 years. Inﬂuenza-
like-illness (ILI) was reported at least once by 185
(27%) of the sample; MRI was reported on at least
one occasion by 390 (60%) individuals, and by 309
(67%) of those who did not report ILI. Thirty-
four percent (220) reported receiving an H1N1v-
containing vaccine either in 2009–2010 (as the ‘swine
ﬂu’ vaccine) or in 2010–2011 (as the seasonal ﬂu vac-
cine). Vaccine uptake during the 2010–2011 inﬂuenza
season was 70% (95% CI 57–82) in participants aged
o65 years, with the majority vaccinated before
November 2010 (Fig. 1). Participants aged<65 years
with an underlying health condition reported a slower
and slightly lower vaccine uptake of 60% (95% CI
49–70). Thirty percent (95% CI 18–47) of healthcare
workers (deﬁned as those who reported having
regular contact with patients) reported receiving the
2010–2011 vaccine, with an increase in uptake co-
inciding with the rise in cases in December 2010 [18].
Participants aged >25 years were signiﬁcantly less
likely (P<0.05) to report ILI than younger partici-
pants (Table 1). Participants receiving the H1N1v
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Fig. 1. Vaccine uptake in ﬂusurvey participants. Cumulative 2010 seasonal inﬂuenza vaccine uptake among ﬂusurvey par-
ticipants across three key groups: participants agedo65 years (red line, circles) ; participants aged<65 years in risk groups
(blue line, squares) and healthcare workers (purple line, diamonds). Bars represent 95% conﬁdence intervals. Also shown
(grey line) is ILI incidence (weekly cases per 100 000), as reported by GP-based surveillance [18]. Date is shown on the
horizontal axis. The launch date of ﬂusurvey for the 2010–2011 season is indicated with a cross (r).
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vaccine either in 2010–2011 alone or both in 2010–
2011 and 2009–2010 were signiﬁcantly less likely
(P<0.01) to report ILI than unvaccinated partici-
pants. Other factors were not statistically signiﬁcant,
although there was a trend for an increased risk of ILI
in individuals who were in a risk group, or had regular
contact with groups of children. In those individuals
who did not report ILI, the risk of MRI was not as-
sociated with any factor except vaccine status : those
reporting H1N1v vaccination in 2010–2011 and
2009–2010 were signiﬁcantly less likely (P=0.029) to
report MRI.
ILI was reported by 14% (26/181) of individuals
vaccinated against H1N1v inﬂuenza in the 2010–2011
season and 34% (159/466) of unvaccinated in-
dividuals, giving a crude estimate of VE of 58% (95%
CI 39–71). Adjusting for other factors, and consider-
ing vaccination in 2010–2011 only, VE against ILI was
estimated to be 52% (95% CI 27–68). Additionally
considering vaccination in 2009–2010, VE against
ILI was estimated to be 46% (95% CI 9–68) for
individuals who received the 2010 seasonal vaccine
only and 59% (95% CI 27–77) for individuals who
received both the 2010 seasonal vaccine and the 2009
pandemic vaccine. In those individuals who did not
report ILI, VE against MRI was estimated to be 25%
(95% CI 3–42) for those receiving H1N1v-containing
vaccines in both the 2009–2010 and 2010–2011
seasons. There was no signiﬁcant protection against
illness during the 2010–2011 season aﬀorded to in-
dividuals who just received the 2009 pandemic vac-
cine, although the number of such participants was
small.
Vaccination was associated with reduced absentee-
ism among participants. In participants aged between
25 and 64 years, 4.1% of vaccinated participants and
11.6% of unvaccinated participants reported taking
time oﬀ work due to symptoms (P<0.001). Of the
participants who took time oﬀ work, vaccinated
participants took an average of 3.4 days oﬀ
Table 1. Multivariate regression analyses of factors related to risk of acquiring ILI or MRI
Ever reporting ILI# Ever reporting MRI$
N NILI RRILI (95% CI) PILI NMRI RRMRI (95% CI) PMRI
Age group (years)
0–24 87 43 — — 32 — —
25–44 278 79 0.70 (0.52–0.94) 0.020* 143 1.00 (0.81–1.24) 0.97
45–64 225 62 0.69 (0.50–0.95) 0.022* 99 0.87 (0.69–1.09) 0.23
o65 57 1 0.05 (0.01–0.39) 0.004** 35 0.93 (0.69–1.26) 0.64
Risk factors
Underlying health condition· 111 29 1.41 (0.99–2.00) 0.054+ 53 1.10 (0.89–1.37) 0.37
Contact with patients 42 14 1.40 (0.89–2.19) 0.14 17 0.91 (0.67–1.24) 0.57
Contacts with children" 108 45 1.29 (0.97–1.71) 0.081+ 42 0.99 (0.81–1.20) 0.89
Contact with crowds of people" 271 74 0.91 (0.71–1.18) 0.49 133 1.01 (0.87–1.17) 0.94
Contact with people agedo65" 28 7 0.73 (0.38–1.44) 0.37 14 1.00 (0.73–1.38) 0.98
>30 min daily on public transport 163 37 0.78 (0.57–1.09) 0.15 87 1.02 (0.87–1.19) 0.80
H1N1v vaccine status
Unvaccinated against H1N1v 427 146 — — 198 — —
H1N1v vaccine in 2009 only 39 13 0.85 (0.53–1.35) 0.49 21 1.14 (0.91–1.42) 0.25
H1N1v vaccine in 2010 only 90 13 0.54 (0.32–0.91) 0.020* 48 0.89 (0.73–1.08) 0.24
H1N1v vaccine 2009 and 2010 91 13 0.41 (0.23–0.73) 0.003** 42 0.75 (0.58–0.97) 0.029*
Total 647 185 309
ILI, Inﬂuenza-like-illness ; MRI, mild respiratory illness ; RR, relative risk ; CI, conﬁdence interval.
# ILI deﬁned as fever plus two or more of runny or blocked nose, sore throat, cough, headache, muscle pain, vomiting,
diarrhoea.
$ MRI deﬁned as ‘not ILI’ plus at least one of runny or blocked nose, sore throat, cough, sneezing. Participants reporting
ILI were excluded from this analysis, so the relevant denominator is given by (N-NILI).
· Deﬁned as taking regular medication for diabetes, asthma, other lung, heart or kidney disorders, being im-
munocompromised or pregnant.
" Contact with more than 10 during the course of a typical day.
* P<0.05, ** P<0.01, + P<0.1.
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and unvaccinated participants took 5.3 days oﬀ
(P<0.001).
The healthcare-seeking behaviour of participants
with symptoms did not vary by vaccine status after
accounting for age and risk groups (RR 0.99, P>0.5).
DISCUSSION
The analysis presented here demonstrates the eﬀec-
tiveness of H1N1v vaccination at reducing reported
ILI and at reducing absenteeism. We found VE at
reducing ILI to be 59% in those receiving H1N1v
vaccination in both 2009–2010 and 2010–2011.
The results are broadly consistent with a randomized
control trial that found that vaccination protected
against ILI, physician visits, and laboratory-
conﬁrmed inﬂuenza in healthy adults when the vac-
cine and circulating viruses were well matched [19]
and with estimates of inﬂuenza vaccine eﬃcacy made
using data from previous seasons [4–8]. Our results
also agree with the ﬁrst published study looking at the
eﬀectiveness of the 2010 seasonal vaccine in the UK
[9], which reports an eﬀectiveness of 46% for
individuals vaccinated in 2010–2011 only and 63% in
individuals vaccinated in both the 2009–2010 and
2010–2011 seasons, and with studies conducted else-
where in Europe [20, 21] (we note that both our esti-
mates and those in other studies [9, 20, 21] have fairly
wide conﬁdence intervals).
The ﬁnding that individuals vaccinated with both
the 2009 pandemic inﬂuenza vaccine and the 2010
seasonal inﬂuenza vaccine may have had slightly el-
evated eﬀectiveness against ILI and were protected
against milder illness is consistent with results recently
published elsewhere [9], and suggests that receipt of
the pandemic vaccine in 2009–2010 may have primed
individuals leading to a better response to the seasonal
vaccine in that year. Further studies are needed to
conﬁrm or refute this.
There are several limitations to the approach taken
here, many of which are discussed elsewhere [11]. The
participants were a self-selecting sample with poten-
tial biases, and in particular the youngest and oldest
age groups were underrepresented. ILI was de-
termined using a symptom-based case deﬁnition, and
therefore inﬂuenza was not laboratory conﬁrmed;
however, ILI as determined here has been shown to
provide a good match to patterns of inﬂuenza inci-
dence [10–12] and the diﬀerence in estimated eﬀec-
tiveness of vaccination against ILI compared to
eﬀectiveness against MRI suggests that ILI is
capturing true inﬂuenza infections. In those in-
dividuals who did not report ILI, H1N1v vaccination
oﬀered some protection against MRI, suggesting that
someMRI cases were actually mild doses of inﬂuenza.
The approach here relies on self-reported symptoms
and vaccination status, which, owing to the anony-
mous nature of the survey, cannot be veriﬁed.
Furthermore, although participants were reminded to
keep their vaccination status updated, we may not
have recorded all vaccinations that took place after
the study began; however, because the study started
before the majority of ILI cases but after the majority
of vaccinations had taken place in the UK (Fig. 1)
[18], it is unlikely that many vaccinations went un-
recorded. In the analysis presented here we have
treated individuals as vaccinated if they received an
H1N1v inﬂuenza vaccine at any point during the
2010–2011 season, hence ‘non-eﬀectiveness ’ of vacci-
nation could be the result of infection taking place
before vaccination; however, because of the timing of
the 2010–2011 UK inﬂuenza season (incidence peak-
ing in late December/early January) [18] almost all
vaccinated individuals had received their vaccination
before being exposed to inﬂuenza, and in our study
there were only two individuals who reported ILI
prior to their date of vaccination.
There are advantages to our approach. First, the
internet-based system collects ILI incidence data
almost in real time, and thus allows us to make
extremely rapid estimates of VE; second, the ap-
proach follows vaccinated and unvaccinated in-
dividuals through the inﬂuenza season rather than
relying on people with ILI accessing healthcare
services, and is therefore free from potential biases
introduced by GP-based estimates of vaccine eﬃcacy;
third, our community-based approach is inexpensive
and can be scaled up to include more participants at
no extra cost. Thus, while our study is relatively small,
involving only about 650 participants, it is hoped
that substantially larger sample sizes will be obtained
in future years as the UK ﬂusurvey becomes more
established.
In common with methods that rely on people visit-
ing their GP, there is no guarantee that our sample is
representative of the population. However, among the
participants in this study the level of vaccine uptake
across various groups closely matches provisional
data from the HPA (according to provisional data
contained in the HPA weekly national inﬂuenza re-
port [18], 72.8% of people in England agedo65 years
had received the 2010 seasonal inﬂuenza vaccine vs.
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70% in our sample; in people aged <65 years in a
risk group the comparable ﬁgures are 50.3% and
60%, respectively; and in healthcare workers pro-
visional data show that 34.2% were vaccinated by the
end of January 2011 vs. 30% in our sample). Thus,
although there may well be other biases in our cohort,
it resembles the UK population in terms of vacci-
nation behaviour. Furthermore, there is no reason to
expect that vaccinated and unvaccinated participants
who exhibit ﬂu-like symptoms would complete the
survey in diﬀerent ways. That traditional methods of
estimating vaccine eﬃcacy and the method presented
here are obliged to make use of potentially biased
samples is an unfortunate reality; we believe that the
method described here, although in need of further
testing over future seasons, is a valuable addition to
existing techniques.
Internet-based monitoring of inﬂuenza in the
community allows real-time surveillance of ILI, rapid
assessment of VE, and an understanding of the wider
impact of illness, which can be used to inform
healthcare providers and the public of the utility
of inﬂuenza vaccination in both resource-rich and
resource-poor settings.
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